Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - Xilio Therapeutics ( NASDAQ:XLO )
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer ( MSS CRC ) without liver metastases
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Stafford, Texas and Tuebingen, Germany, May 31, 2025 - Immatics N.V. ( NASDAQ: IMTX, "Immatics" or the "Company" ) , a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the presentation of expanded data ...
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma 1
Maryland Student Wins NFTE Capital Youth Entrepreneurship Challenge
Washington, DC, May 31, 2025 ( GLOBE NEWSWIRE ) -- Global entrepreneurship education nonprofit Network for Teaching Entrepreneurship ( NFTE ) has named four local student businesses as the winners of its annual Capital Regional Youth Entrepreneurship Challenge.
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
PARIS, France, 31 May 2025 - Late-breaking ( LBA4175 ) post-hoc analysis data from the Phase III NAPOLI 3 study were presented today at the 2025 American Society of Clinical Oncology ( ASCO ) Annual Meeting. These results found a median overall survival ( mOS ) of 19.5 months among long-term ...
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
NEW HAVEN, Conn. and NEW YORK, May 31, 2025 ( GLOBE NEWSWIRE ) -- Arvinas, Inc. ( Nasdaq: ARVN ) and Pfizer Inc. ( NYSE: PFE ) today announced detailed results from the Phase 3 VERITAC-2 clinical trial ( NCT05654623 ) evaluating vepdegestrant monotherapy versus fulvestrant in adults with ...
3 Magnificent Dividend Stocks Down 15% to 64% to Buy and Hold for 20 Years
This is a great time to consider adding quality dividend stocks to your investment portfolio. Recent headwinds in the economy have weighed on sales of leading retail and consumer goods brands, and this has driven their stocks down and their yields higher.While the near term could be rocky, ...
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
• Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to >2.5 years • IMA203 PRAME cell therapy one-time ...
Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ASCO 2025
Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ...
